Junction: Gastrointestinal Stromal Tumor

Obese Populations May Be at Higher Risk for Gastrointestinal Stromal Tumors

Recent studies indicated that individuals who are morbidly obese demonstrated higher incidences of gastrointestinal stromal tumors (GISTs) than the general population, according to a study published in Medicina. Upon further investigation among individuals with obesity who underwent laparoscopic sleeve gastrectomies (LSGs), the incidence rate of GISTs was 0.31%. These GISTs were proven to be low-risk…

New Predictive Model Could Help Differentiate GISTs From Leiomyomas

Researchers in Korea have identified several factors that could differentiate between gastrointestinal stromal tumors (GISTs) and leiomyomas of the stomach.   Age, sex, homogeneity, location of the tumor, and the presence of anechoic spaces, dimpling, or ulcers on an endoscopic ultrasonography are factors that can facilitate the difference between the 2 diseases. This is according…

Laparoscopic Surgery May Be Advantageous for GIST Treatment

Surgical resection is a treatment for individuals with gastrointestinal stromal tumors (GISTs), however, questions have arisen about the highest efficacy among 2 surgical approaches: laparoscopic vs conventional open surgery. While both surgical types resulted in statistically similar rates of long-term patient outcomes such as overall and progression-free survival, laparoscopic surgeries demonstrated more statistically favorable short-term…

Genotype Analysis Can Help Predict Gastrointestinal Stromal Tumor Prognosis

A patient’s genotype is significantly associated with the risk of gastrointestinal stromal tumor (GIST) recurrence, according to a new study published in the Annals of Gastroenterological Surgery. Analyzing a patient’s genotype can therefore help predict disease prognosis and the best treatment approach.  The role of genotypes in the prognosis of GISTs has been controversial. Here,…

Nutritional Status Shown to Have an Effect on GIST Survival Rate

The risk of malnutrition was common among patients with newly diagnosed gastrointestinal stromal tumors (GISTs), and inadequate nutritional status was correlated with a worse clinical prognosis, according to a new study published in Frontiers in Nutrition. Around 77.76% of patients with GISTs were at risk for malnutrition, 12.38% of patients had malnutrition, and 2.29% of…

New AI‑Based Classification System May Improve Diagnosis of GIST

Researchers from Japan have developed a new artificial intelligence (AI)-based system to classify subepithelial lesions (SELs) on endoscopic ultrasonography (EUS) images. This classification system could be useful in distinguishing gastrointestinal stromal tumors (GISTs), the most common SELs, from benign lesions. “The AI system for classifying upper gastrointestinal SELs showed higher diagnostic performance than that of…

Transabdominal Ultrasound Highly Valuable for Predicting Risk of GIST

Researchers discovered transabdominal ultrasounds to be highly valuable in predicting the biological risks of developing gastrointestinal stromal tumors (GISTs), according to a new study published in the Scandinavian Journal of Gastroenterology. The uses of ultrasounds in the context of GISTs are primarily focused on limited parameters, such as diagnosis, treatment, and prognosis evaluation. Guo and…

Vague Imaging Characteristics May Lead to Misdiagnosis of Primary Hepatic GISTs

Researchers from China reported an educational case series of 3 patients with primary hepatic gastrointestinal stromal tumors who were misdiagnosed. They published their new findings in an article that appeared in the Asian Journal of Surgery. Primary hepatic gastrointestinal stromal tumors are mostly misdiagnosed before surgery because they do not have specific symptoms and imaging…

Collaboration Will Help Provide Genomic Testing to GIST Patients

Bayer Pharmaceuticals and The Life Raft Group announced a collaboration to help provide access to comprehensive genomic testing for gastrointestinal stromal tumor (GIST) patients. “By offering comprehensive genomic testing with no charge, many patients will have the opportunity to know what genes are driving their GIST and benefit from genetic-informed care,” Denisse Montoya, patient registry…

Newly Developed Multiplex Network Could Improve Rare Disease Research

Researchers in Austria developed a multiplex network by mapping genes and their interactions on multiple levels, which can help better identify genetic defects and study their consequences.  To build the network, the team led by Jörg Menche, PhD, adjunct principal investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences…

Next post in News Briefs